BACKGROUND: Cardiac resynchronization therapy using a left ventricular (LV) lead inserted via the coronary sinus (CS) improves symptoms of congestive heart failure, decreases hospitalizations, and improves survival. An epicardial LV lead is often placed surgically after a failed percutaneous attempt, but whether it offers the same benefits is unknown. OBJECTIVE: The purpose of this study was to determine if patients who receive a surgical LV lead after failed CS lead placement for cardiac resynchronization therapy derive the same benefit as do patients with a successfully placed CS lead. METHODS: A total of 452 patients underwent attempted CS lead insertion. Forty-five patients who had failed CS lead placement and then had surgical LV lead placement were matched with 135 patients who had successful CS lead placement. RESULTS: No major differences in preoperative variables were seen between groups. Postprocedural complications of acute renal injury (26.2% vs 4.9%, P <.001) and infection (11.9% vs 2.4%, P = .03) were more common in the surgical group. Mean long-term follow-up was 32.4 +/- 17.5 months for surgical patients and 39.4 +/- 14.8 months for percutaneous patients. At follow-up, all-cause mortality (30.6% vs 23.8%, P = .22) and readmission for congestive heart failure (26.2% vs 31.5%, P = .53) were similar between surgical and percutaneous groups. Improvement in New York Heart Association functional class (60.1% vs 49.6%, P = .17) was similar between surgical and percutaneous groups. CONCLUSION: Surgical LV lead placement offers functional benefits similar to those of percutaneous placement but with greater risk of perioperative complications, including acute renal failure and infection. Copyright 2010 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
BACKGROUND: Cardiac resynchronization therapy using a left ventricular (LV) lead inserted via the coronary sinus (CS) improves symptoms of congestive heart failure, decreases hospitalizations, and improves survival. An epicardial LV lead is often placed surgically after a failed percutaneous attempt, but whether it offers the same benefits is unknown. OBJECTIVE: The purpose of this study was to determine if patients who receive a surgical LV lead after failed CS lead placement for cardiac resynchronization therapy derive the same benefit as do patients with a successfully placed CS lead. METHODS: A total of 452 patients underwent attempted CS lead insertion. Forty-five patients who had failed CS lead placement and then had surgical LV lead placement were matched with 135 patients who had successful CS lead placement. RESULTS: No major differences in preoperative variables were seen between groups. Postprocedural complications of acute renal injury (26.2% vs 4.9%, P <.001) and infection (11.9% vs 2.4%, P = .03) were more common in the surgical group. Mean long-term follow-up was 32.4 +/- 17.5 months for surgical patients and 39.4 +/- 14.8 months for percutaneous patients. At follow-up, all-cause mortality (30.6% vs 23.8%, P = .22) and readmission for congestive heart failure (26.2% vs 31.5%, P = .53) were similar between surgical and percutaneous groups. Improvement in New York Heart Association functional class (60.1% vs 49.6%, P = .17) was similar between surgical and percutaneous groups. CONCLUSION: Surgical LV lead placement offers functional benefits similar to those of percutaneous placement but with greater risk of perioperative complications, including acute renal failure and infection. Copyright 2010 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Authors: William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: S Cazeau; C Leclercq; T Lavergne; S Walker; C Varma; C Linde; S Garrigue; L Kappenberger; G A Haywood; M Santini; C Bailleul; J C Daubert Journal: N Engl J Med Date: 2001-03-22 Impact factor: 91.245
Authors: David J Bradley; Elizabeth A Bradley; Kenneth L Baughman; Ronald D Berger; Hugh Calkins; Steven N Goodman; David A Kass; Neil R Powe Journal: JAMA Date: 2003-02-12 Impact factor: 56.272
Authors: Angelo Auricchio; Christoph Stellbrink; Christian Butter; Stefan Sack; Jürgen Vogt; Anand Ramdat Misier; Dirk Böcker; Michael Block; Johannes H Kirkels; Andrew Kramer; Etienne Huvelle Journal: J Am Coll Cardiol Date: 2003-12-17 Impact factor: 24.094
Authors: James B Young; William T Abraham; Andrew L Smith; Angel R Leon; Randy Lieberman; Bruce Wilkoff; Robert C Canby; John S Schroeder; L Bing Liem; Shelley Hall; Kevin Wheelan Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Amy L Miller; Daniel B Kramer; Eldrin F Lewis; Bruce Koplan; Laurence M Epstein; Usha Tedrow Journal: Pacing Clin Electrophysiol Date: 2011-04 Impact factor: 1.976
Authors: Etem Caliskan; Florian Fischer; Felix Schoenrath; Maximilian Y Emmert; Francesco Maisano; Volkmar Falk; Christoph T Starck; Tomas Holubec Journal: J Cardiothorac Surg Date: 2017-11-08 Impact factor: 1.637
Authors: Mohammad A Hossain; Firas Ajam; Hetavi Mahida; Anas Alrefaee; Swapnil Patel; Khushboo Agarwal; Marjan Alidoost; Shereen Dahab; Amy Quinlan; Michael Orange; Arman Mushtaq; Arif Asif Journal: J Clin Med Res Date: 2020-03-02